Compare Kraft Heinz Co (KHC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs TransMedics Group Inc — how do they compare? Kraft Heinz Co trades at $24.55 (market cap $29.23B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Kraft Heinz Co is far larger — about 9.4× TransMedics Group Inc's market cap, and Kraft Heinz Co pays a 6.49% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| KHC | TMDX | |
|---|---|---|
Market Cap | $29.23B | $3.10B |
Sector | Consumer Staples | Technology |
52-Week High | $28.06 | $150.42 |
52-Week Low | $21.21 | $61.99 |
Enterprise Value | $45.55B | $3.49B |
Dividend Yield | 6.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $24.48, down 1.81% on the day, with a bearish technical signal and mixed sentiment. The stock shows attractive valuation ratios like a P/E of 13.04 and P/B of 0.81, but fundamentals are pressured by a net loss of $5.85 billion in 2025 and negative profit margins. Recent quarters have beaten EPS estimates, and the company maintains a $0.40 quarterly dividend, though dividend sustainability concerns persist amid earnings erosion.
The outlook is cautious; while the stock appears undervalued and dividend yield is high, ongoing profit declines and sector headwinds pose risks. Analyst consensus is mixed with a $24 price target, and institutional selling adds pressure. Key catalysts include the success of CEO Cahillane's turnaround strategy, but execution risks and competitive threats remain significant hurdles for shareholder value recovery.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
